0001209191-23-020720.txt : 20230323
0001209191-23-020720.hdr.sgml : 20230323
20230323160522
ACCESSION NUMBER: 0001209191-23-020720
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230321
FILED AS OF DATE: 20230323
DATE AS OF CHANGE: 20230323
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hoerter Steven L.
CENTRAL INDEX KEY: 0001533451
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38219
FILM NUMBER: 23756187
MAIL ADDRESS:
STREET 1: C/O DECIPHERA PHARMACEUTICALS, INC.
STREET 2: 200 SMITH STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Deciphera Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001654151
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 200299725
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 SMITH STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 781-209-6400
MAIL ADDRESS:
STREET 1: 200 SMITH STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
FORMER COMPANY:
FORMER CONFORMED NAME: Deciphera Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20150928
4
1
doc4.xml
FORM 4 SUBMISSION
X0407
4
2023-03-21
0
0001654151
Deciphera Pharmaceuticals, Inc.
DCPH
0001533451
Hoerter Steven L.
C/O DECIPHERA PHARMACEUTICALS, INC.
200 SMITH STREET
WALTHAM
MA
02451
1
1
0
0
President and CEO
0
Common Stock
2023-03-21
4
S
0
7500
15.5709
D
0
D
On March 18, 2019, the Reporting Person was granted 30,000 Restricted Stock Units ("RSUs") which vest in four (4) equal annual installments beginning on March 18, 2020. These RSUs were reported in Table I on a Form 4 filed on March 20, 2019. The sale of shares reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2022.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.395 to $15.70, inclusive. The Reporting Person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
/s/ Jeffrey M. Held, Attorney-in-Fact
2023-03-23